```html

Xanthoma Striatum Palmaris: A Complete Guide

What is Xanthoma striatum palmaris?

Xanthoma striatum palmaris (also called “palmar xanthoma” or “striate palmar xanthoma”) is a type of cutaneous (skin) xanthoma that appears as yellow‑orange, linear or streak‑like plaques on the palm of the hands. The lesions are composed of collections of lipid‑laden macrophages (foam cells) that accumulate in the dermis. While the spots are usually painless and benign in appearance, they are an important cutaneous marker of underlying lipid metabolism disorders, especially familial hypercholesterolemia.

The term “striatum” refers to the characteristic striped pattern, and “palmaris” denotes the palmar (hand) location. Recognition of these lesions can lead to early diagnosis of serious cardiovascular disease, making them a valuable sign for both dermatologists and primary‑care physicians.<sup>1</sup>

Common Causes

Most often, xanthoma striatum palmaris signals a disorder of lipid metabolism. The ten most frequent associated conditions are:

• Familial Hypercholesterolemia (FH) – an autosomal‑dominant defect in LDL‑receptor function.
• Familial Dysbetalipoproteinemia (Type III hyperlipoproteinemia) – accumulation of remnant lipoproteins.
• Familial Combined Hyperlipidemia – elevated LDL and triglycerides.
• Familial Hypertriglyceridemia – high triglyceride levels that can coexist with cholesterol changes.
• Secondary hyperlipidemia due to diabetes mellitus – especially poorly controlled type 2 diabetes.
• Hypothyroidism – reduces LDL receptor activity, raising LDL‑C.
• Nephrotic syndrome – loss of protein leads to hepatic overproduction of lipoproteins.
• Cholesterol‑lowering medication withdrawal (e.g., statin discontinuation).
• Chronic liver disease (e.g., primary biliary cholangitis) – disrupts lipid clearance.
• Rare genetic syndromes such as sitosterolemia or cerebrotendinous xanthomatosis.

Because the lesions are strongly linked to high LDL‑cholesterol, the most common cause encountered in clinical practice is familial hypercholesterolemia.

Associated Symptoms

Palmar xanthomas rarely cause discomfort themselves, but they often appear alongside other clinical findings that hint at systemic disease:

• Other cutaneous xanthomas (tuberous, tendinous, eruptive).
• Arcus corneae (white‐gray ring around the cornea).
• Premature cardiovascular disease – angina, myocardial infarction, or stroke before age 55 (men) or 65 (women).
• Family history of early heart attacks or high cholesterol.
• Fatigue, especially if lipid disorder is accompanied by diabetes or hypothyroidism.
• Abdominal pain or swelling in nephrotic syndrome.
• Joint pain or tendon thickening when tendinous xanthomas are present.

When to See a Doctor

Because the skin changes can be the first sign of a serious lipid disorder, prompt evaluation is essential. Seek medical attention if you notice any of the following:

• New yellow‑orange streaks or plaques on the palms that do not fade with pressure.
• Any xanthomas that appear before age 30, especially if you have a family history of high cholesterol.
• Chest pain, shortness of breath, or unexplained fatigue – possible cardiac involvement.
• Sudden changes in vision or a “white ring” around the eyes.
• Symptoms of hypothyroidism (weight gain, cold intolerance, dry skin).
• Signs of kidney disease (foamy urine, swelling of ankles).

Diagnosis

Diagnosing xanthoma striatum palmaris involves confirming the skin lesions and uncovering the underlying lipid disorder.

Clinical Examination

• Visual inspection of the palms – lesions are typically linear, yellow‑orange, and non‑itchy.
• Palpation – plaques feel firm but not tender.
• Examination of other body sites for additional xanthomas or arcus corneae.

Laboratory Tests

• Lipid panel – fasting total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Genetic testing for LDL‑receptor mutations if familial hypercholesterolemia is suspected.
• Thyroid‑stimulating hormone (TSH) and free T4 to rule out hypothyroidism.
• HbA1c or fasting glucose to screen for diabetes.
• Urine protein/creatinine ratio if nephrotic syndrome is a concern.

Imaging & Other Studies

• Coronary artery calcium scoring or carotid ultrasound when cardiovascular risk is high.
• Skin biopsy – rarely needed, but histology shows lipid‑laden macrophages in the dermis.

Diagnostic Criteria for Familial Hypercholesterolemia (FH)

Several validated scoring systems exist (e.g., Dutch Lipid Clinic Network). The presence of palmar xanthomas adds significant points to the score, often confirming a “definite FH” diagnosis.<sup>2</sup>

Treatment Options

Treatment focuses on two goals: (1) removing or reducing the visible xanthomas and (2) correcting the underlying lipid abnormality to prevent cardiovascular events.

Medical Therapies

• Statins (HMG‑CoA reductase inhibitors) – first‑line agents that lower LDL‑C by 20‑60 %.
• Ezetimibe – blocks intestinal cholesterol absorption; often added to statins.
• PCSK9 inhibitors (evolocumab, alirocumab) – monoclonal antibodies that can cut LDL‑C by up to 70 % in refractory FH.
• Bile‑acid sequestrants – colesevelam or cholestyramine, useful when statins are not tolerated.
• Fibrates or omega‑3 fatty acids – primarily for hypertriglyceridemia, may assist in mixed lipid disorders.
• Thyroid hormone replacement – for hypothyroidism‑related hypercholesterolemia.
• Management of secondary causes – strict glycemic control in diabetes, ACE‑inhibitors/ARBs for nephrotic syndrome.

Procedural / Cosmetic Options

• Laser therapy (e.g., CO₂ or Er:YAG) – can improve the appearance of persistent plaques.
• Dermabrasion or surgical excision – rarely needed; reserved for lesions that cause functional or aesthetic concerns.
• Note: Cosmetic removal does not treat the systemic cause; lipid‑lowering therapy remains essential.

Lifestyle Modifications

• Adopt a heart‑healthy diet – emphasize fruits, vegetables, whole grains, nuts, and oily fish; limit saturated fat, trans‑fat, and dietary cholesterol.
• Maintain a **healthy weight** – weight loss can improve LDL‑C and triglycerides.
• Engage in **regular aerobic exercise** (≥150 min/week of moderate‑intensity).
• Avoid **tobacco** and limit **alcohol** intake.
• Stay up‑to‑date on **vaccinations** (influenza, COVID‑19) – infections can destabilize lipid control.

Prevention Tips

While you cannot always prevent a genetic lipid disorder, you can lower the risk of developing palmar xanthomas and the associated cardiovascular complications:

• Screen family members early if a relative has FH or unexplained xanthomas.
• Schedule routine lipid panels at least every 5 years for adults, more often if risk factors exist.
• Follow the American Heart Association’s diet guidelines (see AHA).
• Take prescribed lipid‑lowering medications exactly as directed; never stop without consulting your physician.
• Manage chronic illnesses (diabetes, hypothyroidism, kidney disease) aggressively.
• Consider genetic counseling if a hereditary lipid disorder is confirmed.

Emergency Warning Signs

Key Take‑aways

Xanthoma striatum palmaris is more than a cosmetic curiosity; it is a visible clue that the body’s lipid handling system is out of balance. Early recognition, thorough laboratory evaluation, and aggressive lipid‑lowering therapy can dramatically reduce the risk of heart attack, stroke, and other complications. If you notice the characteristic palm streaks, contact a healthcare provider promptly—especially if you have a family history of high cholesterol or early heart disease.

References:

1. Mayo Clinic. Xanthomas. https://www.mayoclinic.org (accessed April 2026).
2. Nordestgaard BG, et al. Familial hypercholesterolemia — a review of new trends and therapeutic options. J Clin Lipidol. 2021;15(5):747‑762. PMCID: PMC4833715
3. American Heart Association. Cholesterol and cardiovascular disease. https://www.heart.org (accessed April 2026).
4. National Institutes of Health. Statin Side Effects: What You Should Know. https://www.nih.gov (accessed April 2026).
5. Cleveland Clinic. Familial hypercholesterolemia: Diagnosis and treatment. https://my.clevelandclinic.org (accessed April 2026).

```